Healthy 2026 outlook raises hopes for a mid-term guidance upgrade
25/02/26 -"While Q4 sales met the street’s expectations, H2 25 profitability somewhat exceeded the consensus. Most of the Q4 growth was driven by strong demand for Sandoz’s biosimilars, whereas ..."
Pages
51
Language
English
Published on
25/02/26
You may also be interested by these reports :
25/02/26
While Q4 sales met the street’s expectations, H2 25 profitability somewhat exceeded the consensus. Most of the Q4 growth was driven by strong demand ...
23/02/26
Factoring in the SIFI acquisition (worth nearly 17% of Faes’ current market cap) and Faes Farma’s healthy (+16% topline growth in 9M 25) operating ...
20/02/26
After incorporating the 2025 financials, we have added a new forecast year to our model, which expects a continuation of growth at Novartis. The firm ...
20/02/26
Expanding margins despite moderate topline growth